NSE · PARNAXLAB
Parnax Lab Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹3 Cr with net profit ₹1 Cr — a 33.07% net margin, versus 4.67% the period before.
Shareholding
As of 2026-09-30
- Promoter72.3%
- Public27.7%
3,623 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.51× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #28 of 51 by market cap · medians across 43 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,72,094 Cr | 77.13 | 20.27 | 11.42% | 12.27% |
| Gland Pharma Limited | ₹46,645 Cr | 40.71 | 4.5 | 9.92% | 16.78% |
| Ajanta Pharma Limited | ₹41,035 Cr | 36.16 | 9.06 | 23.33% | 19.65% |
| Rubicon Research Limited | ₹23,578 Cr | 81.82 | 18.3 | 19.14% | 14.89% |
| Shilpa Medicare Ltd. | ₹16,904 Cr | 59.44 | 6.51 | 9.39% | 17.67% |
| Caplin Point Laboratories Ltd. | ₹16,890 Cr | 25.39 | 5.01 | 17.88% | 29.09% |
| Eris Lifesciences Limited | ₹15,199 Cr | 23.14 | 3.9 | 15.87% | 20.04% |
| Marksans Pharma Limited | ₹13,001 Cr | 25.17 | 4.3 | 13.82% | 16.29% |
| Bliss GVS Pharma Ltd. | ₹6,631 Cr | 48.17 | 5.6 | 10.82% | 13.55% |
| Senores Pharmaceuticals Limited | ₹5,597 Cr | 44.29 | 5.99 | 12.36% | 18.59% |
| Parnax Lab Ltd.(this company) | ₹119 Cr | 11.87 | 1.35 | 12.38% | 3.55% |
AI analysis
AI-generated · google/gemini-2.5-flashParnax Lab Ltd. is listed with a market capitalization of Rs 164 Cr. The company reported an EPS of 11.14 and a PE ratio of 12.85. The book value stands at Rs 82.83, with a Return on Equity (ROE) of 12.38% and a Return on Capital Employed (ROCE) of 12.15%. Debt to equity is 0.97. For the fiscal year ending Mar 2025, revenue was Rs 189.41 Cr, and net profit was Rs 11.52 Cr.
Positives
- +The profit margin is high at 474.35%.
- +Return on Equity (ROE) stands at 12.38%.
- +Return on Capital Employed (ROCE) is 12.15%.
Negatives
- −The promoter holding pledge is 9.41% as of June 30, 2026.
- −The debt-to-equity ratio is 0.97, indicating reliance on debt financing.
- −The company has not disclosed quarterly results since Mar 2026.
Financial Performance
For the fiscal year ending Mar 2025, Parnax Lab Ltd. reported revenue of Rs 189.41 Cr and a net profit of Rs 11.52 Cr. Quarterly results show revenue of Rs 69.63 Cr and a net profit of Rs 2.18 Cr for the quarter ending Mar 2026. The EBITDA for the same quarter was Rs 4.84 Cr.
Profitability & Returns
The company's profit margin stood at 474.35%. Return on Equity (ROE) for Parnax Lab Ltd. is 12.38%, and Return on Capital Employed (ROCE) is 12.15%. The earnings per share (EPS) is 11.14.
Balance Sheet
Parnax Lab Ltd. has a debt-to-equity ratio of 0.97. The book value per share is Rs 82.83. The market capitalization is Rs 164 Cr.
Ownership & Pledges
As of June 30, 2026, promoter holding in Parnax Lab Ltd. is 72.30%, while public shareholding is 27.70%. A total of 9.41% of promoter shares are pledged. Specifically, 390,744 shares held by Binoy Baiju Shah (28.53% of total) and 390,744 shares held by Mihir Prakash Shah (34.24% of total) are pledged.
Data as of — price: 2026-10-26 · financials: Jun 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.